Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: May 24, 2017

DrugPatentWatch Database Preview

Bimatoprost - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for bimatoprost and what is the scope of bimatoprost freedom to operate?

is the generic ingredient in three branded drugs marketed by Sandoz Inc, Apotex Inc, Allergan, and Lupin Ltd, and is included in eight NDAs. There are twenty-four patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Bimatoprost has sixty-two patent family members in twenty-one countries.

There are twelve drug master file entries for bimatoprost. Five suppliers are listed for this compound. There are three tentative approvals for this compound.

Summary for Generic Name: bimatoprost

Drug Master File Entries: see list12
Suppliers / Packagers: see list5
Bulk Api Vendors: see list35
Clinical Trials: see list73
Patent Applications: see list2,698
Therapeutic Class:Ophthalmic Agents
Drug Prices:see low prices
DailyMed Link:bimatoprost at DailyMed

Pharmacology for Ingredient: bimatoprost

Drug ClassProstaglandin Analog

Tentative approvals for BIMATOPROST

Applicant Application No. Strength Dosage Form
► Subscribe► Subscribe0.03SOLUTION; OPHTHALMIC
► Subscribe► Subscribe0.01%SOLUTION; OPHTHALMIC
► Subscribe► Subscribe0.01%SOLUTION;OPHTHALMIC
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
SOLUTION/DROPS;OPHTHALMIC022184-001Aug 31, 2010RXYesYes8,338,479► SubscribeY ► Subscribe
SOLUTION/DROPS;OPHTHALMIC022184-001Aug 31, 2010RXYesYes8,524,777► Subscribe ► Subscribe
SOLUTION/DROPS;TOPICAL022369-001Dec 24, 2008ATRXYesYes8,263,054► Subscribe ► Subscribe
SOLUTION/DROPS;TOPICAL022369-001Dec 24, 2008ATRXYesYes8,101,161► Subscribe ► Subscribe
SOLUTION/DROPS;TOPICAL022369-001Dec 24, 2008ATRXYesYes8,541,466► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Subscribe for Complete Access

  • Predict branded drug patent expiration
  • Uncover prior art in abandoned patent applications and expired patents
  • Drug patents and clinical trials in dozens of countries

► Plans and Pricing

Expired Orange Book Patents

 Available with subscription

Paragraph IV Activity

 Available with subscription

Patent Maintenance

 Available with subscription

Non-Orange Book Patents

 Available with subscription

International Patents

 Available with subscription

Supplementary Protection Certificates

 Available with subscription

« Back to the Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:

Google Plus